Barinthus Biotherapeutics’ (BRNS) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reissued their buy rating on shares of Barinthus Biotherapeutics (NASDAQ:BRNS – Free Report) in a research note published on Tuesday, Benzinga reports. HC Wainwright currently has a $15.00 target price on the stock. HC Wainwright also issued estimates for Barinthus Biotherapeutics’ Q4 2023 earnings at ($0.70) EPS, FY2023 earnings at ($2.16) EPS, Q4 […]
More Stories
Winter Weather Cancels Over 1,000 Flights Across US
By Jacki Thrapp Travelers may need to pack their patience on Dec. 27 as winter weather in the Northeast prompted...
Trump Says 2026 Midterms Will Be Referendum on Prices, Economic Success
By Tom Ozimek President Donald Trump said he expects the 2026 midterm elections to hinge on prices and perceptions of...
Canada Offers Ukraine Additional $2.5 Billion in Aid
By Jacki Thrapp Canadian Prime Minister Mark Carney announced on Dec. 27 that Canada will provide an additional $2.5 billion...
Retail in 2025: A Roller Coaster Year—What’s Next in 2026
By Panos Mourdoukoutas The retail industry experienced significant volatility in 2025, as elevated inflation, a weakening labor market, rising household...
North Korean Media Says US-South Korea Submarine Deal Will Spark ‘Hot Arms Race’
By Guy Birchall North Korea’s state media said on Nov. 18 that South Korea’s U.S.-approved plan to build nuclear-powered submarines...
Zelenskyy Says He Will Meet Trump on Sunday to Discuss Peace Plan
By Tom Ozimek Ukrainian President Volodymyr Zelenskyy said on Dec. 26 that he will meet President Donald Trump in Florida...